Ocrelizumab real-world safety in the treatment of multiple sclerosis (MS): Differences between investigator-reported and patient-reported safety

Authors
Category Primary study
JournalNeurology
Year 2020
This article has no abstract
Epistemonikos ID: 95ccd678f24bd1aa4dc94a4d4a42dd2d82784319
First added on: Feb 12, 2025